Anti-VEGF: Looking Forward in Lung Cancer

Click here to register and receive credit for this CME activity
Up to 3 AMA PRA Category 1 Credits

Issues and Opportunities in Treating Lung Cancer Today
Thomas J. Lynch, Jr, MD, Chief, Hematology/Oncology
Massachusetts General Hospital Cancer Center, Boston

Rationale for VEGF as a Target in Lung Cancer
Rebecca Suk Heist, MD, MPH, Department of Oncology
Massachusetts General Hospital Cancer Center, Boston

Monoclonal Antibody-based Anti-VEGF Therapy
Tracey L. Evans, MD, Department of Medicine
University of Pennsylvania School of Medicine, Philadelphia

Receptor Tyrosine Kinase Inhibitors of VEGF
Mark A. Socinski, MD, Lineberger Comprehensive Cancer Center
University of North Carolina, Chapel Hill

Combination VEGF/EGFR Therapies
Edward S. Kim, MD, and Emer Hanrahan, MD, Department of Medicine
The University of Texas M.D. Anderson Cancer Center, Houston

Supported by an educational grant from Genentech